# Who does AbCellera Biologics pay? Who are its key suppliers?
Canonical: https://valuechain.wiki/abcellera · Facet: suppliers · Updated: 2026-10-09T16:08:10.423123+00:00 · Source: ValueChain.wiki (cited money-flow graph)

**Citable summary**: AbCellera Biologics discloses no named confirmed suppliers/cost counterparties; 2 relationships are tracked as undisclosed/aggregate. Per the valuechain.wiki graph: 2 cost edges, backed by 3 dated sources, 3 of them primary filings (as of 2026-10-09).

### Beedie JV (신규 연구동, 지분 50%) (high)
- metric: equity investment $53.8 · 2026-06-30 · 10-Q equity-method investment balance
- note: A 50% joint venture building 220,000 sq ft of lab and office space in Vancouver. Equity-method balance $53.8M at end-June 2026; to be leased or sublet on completion.
- [confirms] SEC EDGAR (AbCellera 10-Q) (EN, filing, published 2026-08-05) https://www.sec.gov/Archives/edgar/data/1703057/000170305726000046/abcl-20260630.htm: ""The Company has entered into two separate 50 % joint ventures, Dayhu JV and Beedie JV" ... "Beedie JV As of December 31, 2025 and June 30, 2026, the equity investment balance was $ 51.8 million and $ 53.8 million""
- [confirms] SEC EDGAR (AbCellera 10-K) (EN, filing, published 2026-02-24) https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm: ""Through our Beedie joint venture, we are nearing the completion of construction of 220,000 square feet of additional lab and office space.""

### Dayhu JV (본사 사옥, 지분 50%) (high)
- metric: equity investment $10.8 · 2025-12-31 · 10-K equity-method investment balance
- note: A 50% joint venture owning the 167,000 sq ft headquarters completed in 2024. After a December 2025 loan secured on the building and a distribution, the equity balance fell from $41.0M to $10.8M.
- [confirms] SEC EDGAR (AbCellera 10-K) (EN, filing, published 2026-02-24) https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm: ""As of December 31, 2024 and December 31, 2025, the equity investment balance was $ 41.0 million and $ 10.8 million, respectively, of which substantially all the assets in the Dayhu JV are comprised of property and equipment.""

### Dayhu JV (본사 임차료) (high)
- metric: cost $2.5 · 2026 H1 · 10-Q lease expense to Dayhu JV (operating expenses)
- note: Leases its headquarters from the joint venture. Lease expense $2.5M in H1 2026, lease liability $44.2M at end-June. Leases expire from 2037.
- [confirms] SEC EDGAR (AbCellera 10-Q) (EN, filing, published 2026-08-05) https://www.sec.gov/Archives/edgar/data/1703057/000170305726000046/abcl-20260630.htm: ""an operating lease liability of $ 46.7 million and $ 44.2 million, respectively, associated with an office lease with the Dayhu JV. The Company incurred lease expense to the Dayhu JV ... $ 2.5 million and $ 2.5 million for the six months ended June 30, 2025 and 2026 respectively.""

### 습식랩·시퀀싱·임상 (비공개) (mid)
- metric: cost $12.2 · FY2026 약정 · 10-K clinical/CRO/manufacturing commitments (within one year)
- note: $12.2M of commitments due within a year to clinical-trial organizations, CROs and internal manufacturing (end-2025). Counterparties undisclosed.
- [confirms] SEC EDGAR (AbCellera 10-K) (EN, filing, published 2026-02-24) https://www.sec.gov/Archives/edgar/data/1703057/000170305726000012/abcl-20251231.htm: ""the Company has $12.2 million of commitments as of December 31, 2025 related to ongoing clinical trials with third-party organizations, contract research organizations, and internal manufacturing capabilities which the Company expects to incur within one year.""
- [confirms] SEC/StockTitan (EN, filing, published 2026-02-01) https://www.stocktitan.net/sec-filings/ABCL/10-k-ab-cellera-biologics-inc-files-annual-report-a6d1b7c6684c.html: "Single-cell screening, wet-lab and clinical work."

Reverse side: https://valuechain.wiki/abcellera/customers.md · Ripple: https://valuechain.wiki/abcellera/ripple.md

---
Full node: https://valuechain.wiki/abcellera.md · JSON: https://valuechain.wiki/abcellera.json